Citius Oncology (CTOR) Q1 2026 earnings summary

Executive summary

• Achieved first commercial revenue of $3.94 million in December 2025 with the launch of LYMPHIR, an oncology immunotherapy for cutaneous T-cell lymphoma (CTCL), following FDA approval in August 2024.

• Transitioned from a development-stage to a commercial-stage oncology company, focusing on accelerating physician adoption and expanding patient access using an AI-enabled commercial platform.

• Net loss for the quarter was $5.53 million, an improvement from $6.66 million in the prior year period, driven by gross profit from initial product sales.

• Advanced international access through regional partners and Named Patient Programs in Europe and the Middle East.

• Company remains dependent on external financing and support from its parent, with substantial doubt about its ability to continue as a going concern beyond May 2026.

Financial highlights

• Net revenue for the quarter was $3.94 million, with gross profit of $3.2 million (80% gross margin).

• Operating expenses totaled $8.41 million, up from $6.39 million year-over-year, mainly due to increased stock-based compensation.

• Net loss for the quarter was $5.5 million, or $(0.06) per share, compared to $(0.09) per share in the prior-year period.

• Cash and cash equivalents at quarter-end were $7.3 million; negative working capital of $7.6 million.

• Net proceeds of $15.1 million were raised from a December 2025 equity offering.

Outlook and guidance

• Sufficient funds are expected to support operations through May 2026; additional capital will be required thereafter.

• Revenue is anticipated to grow as LYMPHIR gains market acceptance, with ongoing efforts to expand field presence and drive efficient market penetration.

• Strategic alternatives are being evaluated with Jefferies LLC as exclusive financial advisor.

• Investigator-initiated Phase I studies underway for potential label expansion, including combinations with pembrolizumab and as part of lymphodepletion regimens before CAR-T therapy.